Clinical Studies


Phase 2 – Post-Traumatic Stress Disorder

A randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of 50 mg NYX-783 once daily vs. placebo in participants with post-traumatic stress disorder (PTSD) — For more information, visit

Phase 1 – Opioid Use Disorder

A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of NYX-783 50 mg and 150 mg, in combination with oxycodone 15 mg and 30 mg, in individuals who use opioids.  — For more information, visit


Phase 2 – Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

A first-in-patient, randomized, double-blind, placebo-controlled study to evaluate NYX-458 in subjects with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies — For more information, visit